| scholarly article | Q13442814 |
| P50 | author | Thomas Waldmann | Q21042387 |
| Stefania Pittaluga | Q87358458 | ||
| Maryalice Stetler-Stevenson | Q90926259 | ||
| P2093 | author name string | John C Morris | |
| Paul S Albert | |||
| Helen Matthews | |||
| Mark Raffeld | |||
| Deirdre O'Mahony | |||
| John E Janik | |||
| Margaret R Brown | |||
| Karen Kaucic | |||
| Luz Hammershaimb | |||
| Thomas Fleisher | |||
| Dirk Reitsma | |||
| P2860 | cites work | A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 |
| The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3 | Q28285374 | ||
| Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation | Q33183745 | ||
| Malignant lymphomas in transplantation patients | Q33753089 | ||
| Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting | Q33789613 | ||
| Post-transplant lymphoproliferative disorders | Q34386170 | ||
| Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases | Q35110895 | ||
| Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia | Q35751004 | ||
| The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression | Q35818660 | ||
| Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms | Q39400395 | ||
| Posttransplant lymphoproliferative disease: a series of 23 cases. | Q40465044 | ||
| Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients | Q40602356 | ||
| Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients | Q40625214 | ||
| Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity | Q40840303 | ||
| Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. | Q41009723 | ||
| Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. | Q41561745 | ||
| A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease | Q43405471 | ||
| Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms | Q43972946 | ||
| Epstein-Barr virus-positive aggressive lymphoma as a consequence of immunosuppression after multiple salvage treatments for follicular lymphoma | Q44478505 | ||
| Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? | Q44595699 | ||
| Epstein-Barr virus–associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine | Q44625230 | ||
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. | Q44776010 | ||
| Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. | Q44796944 | ||
| Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia | Q45005125 | ||
| Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification | Q45059029 | ||
| Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. | Q45416593 | ||
| Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease | Q45759125 | ||
| Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. | Q45759216 | ||
| Cyclosporin A and Epstein-Barr virus | Q45806678 | ||
| Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma | Q45844350 | ||
| World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. | Q46038765 | ||
| Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience | Q46426412 | ||
| Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study | Q46778140 | ||
| Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. | Q55239617 | ||
| Lymphoproliferative disorders in renal transplant patients in Japan. | Q55239843 | ||
| The immune response to primary EBV infection: a role for natural killer cells | Q62583514 | ||
| A novel murine model for the assessment of human CD2-related reagents in vivo | Q71396654 | ||
| An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites | Q72231532 | ||
| Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders | Q72386152 | ||
| CD2 regulates the positive selection and function of antigen-specific CD4- CD8+ T cells | Q73063943 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 2514-2522 | |
| P577 | publication date | 2009-03-17 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. | |
| P478 | volume | 15 |
| Q42333450 | 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. |
| Q35056539 | Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells. |
| Q37605247 | Antibody-based therapy of leukaemia |
| Q36422133 | Clinical Trials and Treatment of ATL. |
| Q37893414 | Emerging antibody combinations in oncology |
| Q49165089 | Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis? |
| Q35022833 | Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) |
| Q38186617 | From empiric to mechanism-based therapy for peripheral T cell lymphoma. |
| Q47562043 | HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment |
| Q37123276 | High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. |
| Q30238757 | Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options |
| Q36682843 | Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia |
| Q37738565 | Natural killer-cell neoplasms |
| Q37854715 | New drug therapies in peripheral T-cell lymphoma |
| Q37807160 | New drugs for aggressive B-cell and T-cell lymphomas |
| Q34683488 | New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies |
| Q37701472 | New targets of therapy in T-cell lymphomas |
| Q57468335 | Novel Immunotherapies for T Cell Lymphoma and Leukemia |
| Q84774081 | Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma |
| Q38113568 | Peripheral T-cell lymphomas: a review of current approaches and hopes for the future |
| Q48185230 | Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. |
| Q38963375 | Restoring Regulatory T Cells in Type 1 Diabetes |
| Q30244553 | T-cell lymphomas, a challenging disease: types, treatments, and future. |
Search more.